These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 27890396)

  • 1. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
    Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
    Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
    Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
    Dale JB; Penfound TA; Chiang EY; Walton WJ
    Vaccine; 2011 Oct; 29(46):8175-8. PubMed ID: 21920403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
    Aranha MP; Penfound TA; Spencer JA; Agarwal R; Baudry J; Dale JB; Smith JC
    J Biol Chem; 2020 Mar; 295(12):3826-3836. PubMed ID: 32029479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
    Smeesters PR; Dramaix M; Van Melderen L
    Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
    Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
    J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
    Finn MB; Penfound TA; Salehi S; Ogega CO; Dold C; Plante O; Dale JB
    Vaccine; 2024 Sep; 42(22):126205. PubMed ID: 39141987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity.
    Frost HR; Laho D; Sanderson-Smith ML; Licciardi P; Donath S; Curtis N; Kado J; Dale JB; Steer AC; Smeesters PR
    Clin Infect Dis; 2017 Oct; 65(9):1523-1531. PubMed ID: 29020160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.
    Bruner M; James A; Beall B; Carlone GM; Ades E; Johnson S; Guarner J; Sampson J
    Vaccine; 2003 Jun; 21(21-22):2698-703. PubMed ID: 12798606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines.
    Aranha MP; Penfound TA; Salehi S; Botteaux A; Smeesters P; Dale JB; Smith JC
    J Immunol; 2021 Aug; 207(4):1138-1149. PubMed ID: 34341168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a 26-valent group A streptococcal vaccine.
    Hu MC; Walls MA; Stroop SD; Reddish MA; Beall B; Dale JB
    Infect Immun; 2002 Apr; 70(4):2171-7. PubMed ID: 11895984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant tetravalent group A streptococcal M protein vaccine.
    Dale JB; Chiang EY; Lederer JW
    J Immunol; 1993 Aug; 151(4):2188-94. PubMed ID: 8345202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group A streptococcus expresses a trio of surface proteins containing protective epitopes.
    Niedermeyer SE; Penfound TA; Hohn C; Li Y; Homayouni R; Zhao J; Dale JB
    Clin Vaccine Immunol; 2014 Oct; 21(10):1421-5. PubMed ID: 25080552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
    Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
    Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
    Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.